# Fortrea Holdings Inc.: financial statements, quarterly

FTRE · Nasdaq · CIK 1965040 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ftre.md) · [Financials](/companies/ftre/financials.md) · [Filings](/companies/ftre/filings.md) · [Insiders](/companies/ftre/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ftre/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [710 d](/filings/0001628280-26-012244.md) | [662](/filings/0001965040-25-000027.md) | [662](/filings/0001965040-25-000050.md) | [675](/filings/0001628280-25-049522.md) | [697 d](/filings/0001628280-26-012244.md) | [651](/filings/0001628280-26-030496.md) | [710](/filings/0001628280-26-050597.md) | [701](/filings/0001628280-26-068248.md) | [661 d](/filings/0001628280-26-012244.md) | [637](/filings/0001628280-26-030496.md) | [678](/filings/0001628280-26-050597.md) | [692](/filings/0001628280-26-068248.md) |
| Selling, general and administrative | $m | [127 d](/filings/0001628280-26-012244.md) | [120](/filings/0001965040-25-000027.md) | [156](/filings/0001965040-25-000050.md) | [136](/filings/0001628280-25-049522.md) | [148 d](/filings/0001628280-26-012244.md) | [122](/filings/0001628280-26-030496.md) | [125](/filings/0001628280-26-050597.md) | [107](/filings/0001628280-26-068248.md) | [103 d](/filings/0001628280-26-012244.md) | [101](/filings/0001628280-26-030496.md) | [102](/filings/0001628280-26-050597.md) | [104](/filings/0001628280-26-068248.md) |
| Operating income | $m | [(24.0) d](/filings/0001628280-26-012244.md) | [(37.4)](/filings/0001965040-25-000027.md) | [(50.9)](/filings/0001965040-25-000050.md) | [(18.0)](/filings/0001628280-25-049522.md) | [(55.6) d](/filings/0001628280-26-012244.md) | [(520)](/filings/0001628280-26-030496.md) | [(330)](/filings/0001628280-26-050597.md) | [(8.6)](/filings/0001628280-26-068248.md) | [(13.6) d](/filings/0001628280-26-012244.md) | [(3.4)](/filings/0001628280-26-030496.md) | [14.8](/filings/0001628280-26-050597.md) | [15.0](/filings/0001628280-26-068248.md) |
| Interest expense | $m | [34.5 d](/filings/0001965040-24-000010.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(6.1) d](/filings/0001628280-26-012244.md) | [4.1](/filings/0001965040-25-000027.md) | [10.7](/filings/0001965040-25-000050.md) | [(17.3)](/filings/0001628280-25-049522.md) | [(1.0) d](/filings/0001628280-26-012244.md) | [14.9](/filings/0001628280-26-030496.md) | [4.2](/filings/0001628280-26-050597.md) | [(12.8)](/filings/0001628280-26-068248.md) | [(3.1) d](/filings/0001628280-26-012244.md) | [11.3](/filings/0001628280-26-030496.md) | [12.0](/filings/0001628280-26-050597.md) | [(4.2)](/filings/0001628280-26-068248.md) |
| Net income | $m | [(54.5) d](/filings/0001628280-26-012244.md) | [(101)](/filings/0001628280-25-049522.md) | [(138)](/filings/0001628280-25-049522.md) | [(27.9)](/filings/0001628280-25-049522.md) | [(61.2) d](/filings/0001628280-26-012244.md) | [(563)](/filings/0001628280-26-068248.md) | [(375)](/filings/0001628280-26-068248.md) | [(15.9)](/filings/0001628280-26-068248.md) | [(32.5) d](/filings/0001628280-26-012244.md) | [(23.6)](/filings/0001628280-26-068248.md) | [(13.2)](/filings/0001628280-26-068248.md) | [0.6](/filings/0001628280-26-068248.md) |
| Diluted EPS | $ per share | not reported | [(1.13)](/filings/0001965040-25-000027.md) | [(1.55)](/filings/0001965040-25-000050.md) | [(0.31)](/filings/0001628280-25-049522.md) | not reported | [(6.25)](/filings/0001628280-26-030496.md) | [(4.14)](/filings/0001628280-26-050597.md) | [(0.17)](/filings/0001628280-26-068248.md) | not reported | [(0.25)](/filings/0001628280-26-030496.md) | [(0.14)](/filings/0001628280-26-050597.md) | [0.01](/filings/0001628280-26-068248.md) |
| Basic EPS | $ per share | not reported | [(1.13)](/filings/0001965040-25-000027.md) | [(1.55)](/filings/0001965040-25-000050.md) | [(0.31)](/filings/0001628280-25-049522.md) | not reported | [(6.25)](/filings/0001628280-26-030496.md) | [(4.14)](/filings/0001628280-26-050597.md) | [(0.17)](/filings/0001628280-26-068248.md) | not reported | [(0.25)](/filings/0001628280-26-030496.md) | [(0.14)](/filings/0001628280-26-050597.md) | [0.01](/filings/0001628280-26-068248.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [109](/filings/0001965040-25-000015.md) | [92.8](/filings/0001965040-24-000036.md) | [126](/filings/0001965040-24-000054.md) | [105](/filings/0001965040-24-000064.md) | [119](/filings/0001628280-26-012244.md) | [102](/filings/0001965040-25-000027.md) | [81.2](/filings/0001965040-25-000050.md) | [131](/filings/0001628280-25-049522.md) | [175](/filings/0001628280-26-068248.md) | [148](/filings/0001628280-26-030496.md) | [169](/filings/0001628280-26-050597.md) | [221](/filings/0001628280-26-068248.md) |
| Current assets | $m | [1,251](/filings/0001965040-25-000015.md) | [1,200](/filings/0001965040-24-000036.md) | [888](/filings/0001965040-24-000054.md) | [937](/filings/0001965040-24-000064.md) | [948](/filings/0001628280-26-012244.md) | [970](/filings/0001965040-25-000027.md) | [960](/filings/0001965040-25-000050.md) | [919](/filings/0001628280-25-049522.md) | [897](/filings/0001628280-26-068248.md) | [882](/filings/0001628280-26-030496.md) | [924](/filings/0001628280-26-050597.md) | [953](/filings/0001628280-26-068248.md) |
| Total assets | $m | [4,333](/filings/0001965040-25-000015.md) | [4,240](/filings/0001965040-24-000036.md) | [3,565](/filings/0001965040-24-000054.md) | [3,664](/filings/0001965040-24-000064.md) | [3,579](/filings/0001628280-26-012244.md) | [3,121](/filings/0001965040-25-000027.md) | [2,835](/filings/0001965040-25-000050.md) | [2,742](/filings/0001628280-25-049522.md) | [2,716](/filings/0001628280-26-068248.md) | [2,683](/filings/0001628280-26-030496.md) | [2,715](/filings/0001628280-26-050597.md) | [2,738](/filings/0001628280-26-068248.md) |
| Current liabilities | $m | [778](/filings/0001965040-25-000015.md) | [818](/filings/0001965040-24-000036.md) | [749](/filings/0001965040-24-000054.md) | [796](/filings/0001965040-24-000064.md) | [950](/filings/0001628280-26-012244.md) | [999](/filings/0001965040-25-000027.md) | [942](/filings/0001965040-25-000050.md) | [914](/filings/0001628280-25-049522.md) | [913](/filings/0001628280-26-068248.md) | [929](/filings/0001628280-26-030496.md) | [964](/filings/0001628280-26-050597.md) | [983](/filings/0001628280-26-068248.md) |
| Total liabilities | $m | [2,619](/filings/0001965040-25-000015.md) | [2,648](/filings/0001965040-24-000036.md) | [2,104](/filings/0001965040-24-000054.md) | [2,150](/filings/0001965040-24-000064.md) | [2,217](/filings/0001628280-26-012244.md) | [2,262](/filings/0001965040-25-000027.md) | [2,246](/filings/0001965040-25-000050.md) | [2,161](/filings/0001628280-25-049522.md) | [2,152](/filings/0001628280-26-068248.md) | [2,158](/filings/0001628280-26-030496.md) | [2,191](/filings/0001628280-26-050597.md) | [2,206](/filings/0001628280-26-068248.md) |
| Long-term debt | $m | [1,566](/filings/0001965040-25-000015.md) | [1,559](/filings/0001965040-24-000036.md) | [1,124](/filings/0001965040-24-000054.md) | [1,125](/filings/0001965040-24-000064.md) | [1,050](/filings/0001628280-26-012244.md) | [1,050](/filings/0001965040-25-000027.md) | [1,101](/filings/0001965040-25-000050.md) | [1,052](/filings/0001628280-25-049522.md) | [1,048](/filings/0001628280-26-068248.md) | [1,043](/filings/0001628280-26-030496.md) | [1,037](/filings/0001628280-26-050597.md) | [1,032](/filings/0001628280-26-068248.md) |
| Current portion of debt | $m | [26.1](/filings/0001965040-25-000015.md) | [55.0](/filings/0001965040-24-000036.md) | [0.0](/filings/0001965040-24-000054.md) | [0.0](/filings/0001965040-24-000064.md) | [74.8](/filings/0001628280-26-012244.md) | [164](/filings/0001965040-25-000027.md) | [74.8](/filings/0001965040-25-000050.md) | [74.5](/filings/0001628280-25-049522.md) | [4.8](/filings/0001628280-26-068248.md) | [10.9](/filings/0001628280-26-030496.md) | [17.1](/filings/0001628280-26-050597.md) | [23.4](/filings/0001628280-26-068248.md) |
| Shareholders' equity | $m | [1,714](/filings/0001628280-26-012244.md) | [1,592](/filings/0001628280-25-049522.md) | [1,461](/filings/0001628280-25-049522.md) | [1,514](/filings/0001628280-25-049522.md) | [1,362](/filings/0001628280-26-068248.md) | [859](/filings/0001628280-26-068248.md) | [589](/filings/0001628280-26-068248.md) | [581](/filings/0001628280-26-068248.md) | [564](/filings/0001628280-26-068248.md) | [526](/filings/0001628280-26-068248.md) | [524](/filings/0001628280-26-068248.md) | [532](/filings/0001628280-26-068248.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [18.4 d](/filings/0001628280-26-012244.md) | [(25.6)](/filings/0001965040-25-000027.md) | [274 d](/filings/0001965040-25-000050.md) | [(2.4) d](/filings/0001628280-25-049522.md) | [17.1 d](/filings/0001628280-26-012244.md) | [(124)](/filings/0001628280-26-030496.md) | [21.8 d](/filings/0001628280-26-050597.md) | [86.8 d](/filings/0001628280-26-068248.md) | [129 d](/filings/0001628280-26-012244.md) | [(17.0)](/filings/0001628280-26-030496.md) | [28.9 d](/filings/0001628280-26-050597.md) | [60.8 d](/filings/0001628280-26-068248.md) |
| Capital expenditure | $m | [9.4 d](/filings/0001628280-26-012244.md) | [9.3](/filings/0001965040-25-000027.md) | [11.2 d](/filings/0001965040-25-000050.md) | [8.2 d](/filings/0001628280-25-049522.md) | [(3.2) d](/filings/0001628280-26-012244.md) | [2.9](/filings/0001628280-26-030496.md) | [7.5 d](/filings/0001628280-26-050597.md) | [7.3 d](/filings/0001628280-26-068248.md) | [7.5 d](/filings/0001628280-26-012244.md) | [8.0](/filings/0001628280-26-030496.md) | [9.0 d](/filings/0001628280-26-050597.md) | [8.3 d](/filings/0001628280-26-068248.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | period not labelled (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [88.8](/filings/0001965040-24-000036.md) | [88.8](/filings/0001965040-24-000054.md) | [88.8](/filings/0001965040-24-000064.md) | [89.2](/filings/0001965040-24-000036.md) | [89.4](/filings/0001965040-24-000054.md) | [89.6](/filings/0001965040-24-000064.md) | [90.1](/filings/0001628280-26-030496.md) | [90.6](/filings/0001628280-26-050597.md) | [91.2](/filings/0001628280-26-068248.md) | [93.6](/filings/0001628280-26-030496.md) | [94.8](/filings/0001628280-26-050597.md) | [101](/filings/0001628280-26-068248.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 96,500,000 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0001628280-26-068248.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 17:51 ET. No prices; not investment advice.